CombiGene chooses CDMO partner for the COZY01 pain project
September 15, 2023
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company, after a thorough evaluation process,
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company, after a thorough evaluation process,
Read CombiGene’s newsletter in English here. Ingeneious issue no 4 2023 mobile friendly Contacts CombiGene AB
In June, CombiGene and Spark Therapeutics held a bi-annual Joint Research Committee meeting in Stockholm, Sweden,
April – June 2023• Net sales: TSEK 1,788 (4,738).• Other operating revenues: TSEK 1,413 (9,800).• Profit
CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
In January 2023, CombiGene AB (“CombiGene”, the “Company”) and the Danish company Zyneyro ApS announced a
Read CombiGene’s newsletter in English here. Ingeneious issue no 3 2023 mobile friendly Contacts Jan Nilsson,
The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ)
Read CombiGene’s newsletter in English here. Ingeneious issue no 2 2023 mobile friendly Contacts Jan Nilsson,
Vinnova supports the formation of a Nordic CCRM hub Vinnova, Sweden’s Innovation Agency, has granted funding